We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Cubist Pharmaceuticals entered into definitive agreements to purchase from Eli
Lilly and company a 2 percent reduction in the royalties payable to Lilly on
net sales of Cubicin (daptomycin for injection).
Interleukin Genetics has signed two new research agreements with Access Business
Group, a subsidiary of Alticor. The company also reported that it has modified
its stock purchase and distribution agreements with other affiliates of Alticor.
French biopharmaceutical firm Flamel Technologies SA said it terminated the
company's license agreement with Biovail Laboratories Inc. for Genvir, Flamel's
oral controlled-release form of acyclovir for the treatment of genital herpes.
Publicly traded drugmaker Allos Therapeutics announced Thursday, March 3, it
secured $50 million in private equity from Warburg Pincus to help bring its
lead cancer medicine to market.
Corixa, a developer of immunotherapeutics, and Lorantis,
a Cambridge, UK-based immunotherapy company, have announced a joint collaboration
in which the companies will continue the development of a therapeutic hepatitis
B vaccine, containing Corixa's RC-529 adjuvant and Lorantis' CV-1831, a hepatitis
B core antigen that was previously owned by Apovia.
Although the pharmaceutical industry has been criticized in recent years for
its lack of productivity on the R&D front, there are a number of promising
products -- either newly approved or soon-to-be-approved -- that could give big
pharma firms a boost in 2005 and beyond, according to a new research report
from Standard & Poor's (S&P).
A top Democratic representative is prodding the SEC to take a harder look at
how pharmaceutical companies disclose information about postmarketing studies
to shareholders.
Although Rep. Henry Waxman (D-Calif.) continues
to support the Hatch-Waxman Act, he acknowledged recently that the law is not
a complete solution to the problems generic drugmakers face in trying to bring
new products to market, particularly generic biologic products.
The Good Automated Manufacturing Practice (GAMP) Forum, a division of the International
Society for Pharmaceutical Engineering (ISPE), has released its "GAMP Good
Practice Guide: A Risk-Based Approach to Compliant Electronic Records and Signatures."